BC Extra | May 28, 2019
Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

A licensing deal with Lilly for an analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion will receive $47.5 million up front and is eligible for $950 million...
BC Week In Review | Nov 30, 2018
Financial News

Centrexion steps back from IPO amid volatile market

Centrexion Therapeutics Corp. (Boston, Mass.) told BioCentury on Nov. 16 that it will not be moving forward with its NASDAQ IPO. The decision by the pain company comes as market volatility has increased and several...
BC Extra | Nov 17, 2018
Financial News

Centrexion steps back from IPO amid volatile market

A decision by pain company Centrexion Therapeutics Corp. (Boston, Mass.) to not move forward with its NASDAQ IPO comes as market volatility has increased and several biotechs have failed to hit their desired valuations. In...
BC Week In Review | Oct 26, 2018
Financial News

Pain company Centrexion proposes NASDAQ IPO

Pain company Centrexion Therapeutics Corp. (Boston, Mass.) proposed to raise up to $86.3 million in an IPO on NASDAQ. BofA Merrill Lynch, Leerink and Evercore ISI are underwriters. Centrexion expects top-line results from the Phase...
BC Extra | Oct 9, 2018
Politics & Policy

FDA pushes generic competition for transdermal complex drugs

FDA clarified how to develop generic versions of transdermal or topical complex drugs, releasing a series of guidances Tuesday as the agency continues its push for greater generics competition. Complex drugs, especially those with transdermal...
BC Innovations | May 23, 2018
Distillery Therapeutics

Neurology; dermatology

INDICATION: Pain; itch Cell culture and mouse studies identified an esterase-cleavable capsaicin-based TRPV1 antagonist that could help treat pain and itch without systemic side effects associated with other TRPV1 antagonists. Chemical synthesis and testing in...
BC Week In Review | May 14, 2018
Clinical News

Concentric reports Phase Ib data for non-opioid postsurgical pain candidate

Concentric Analgesics Inc. (San Francisco, Calif.) reported top-line data from a Phase Ib trial to treat postsurgical pain following a bunionectomy showing that the highest dose of a single intraoperative injection of CA-008 led to...
BC Innovations | Feb 14, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Cell culture and mouse studies suggest inhibiting S. aureus AgrA or activating TRPV1 could help treat S. aureus -induced pain. In co-cultures of mouse dorsal root ganglion cells and S. aureus , knockout of...
BC Week In Review | Jan 5, 2018
Financial News

Centrexion raises $67M in series D

Centrexion Therapeutics Corp. (Boston, Mass.) raised $67 million on Jan. 2 in a series D round led by New Enterprise Associates, with participation by Quan Capital, ArrowMark Partners, funds advised by Clough Capital Partners, InterWest...
BC Extra | Jan 2, 2018
Financial News

Centrexion raises $67M in series D

Centrexion Therapeutics Corp. (Boston, Mass.) said Tuesday it raised $67 million in a series D round led by New Enterprise Associates, with participation by Quan Capital, ArrowMark Partners, funds advised by Clough Capital Partners, InterWest...
Items per page:
1 - 10 of 238